Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 27, 2012 (14 years ago)

Levetiracetam Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Adulterated Presence of Foreign Tablets: Pharmaceutical manufacturer may have distributed foreign tablets in bottles of Levetiracetam Tablets, USP 500 mg.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Levetiracetam Tablets, USP 500 mg, 500 count bottle, Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 USA, NDC 0378-5615-05

Affected NDC 0378-5615-05

Compare with the code on your package — it is the most precise check available.

Drug: Levetiracetam

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Levetiracetam
NDC 00378-5615
500 mg/1 Tablet, Film Coated
Oral
Mylan Pharmaceuticals Inc. Rx
Recalling firm
Mylan Pharmaceuticals Inc.
NDC code
0378-5615-05
Origin
WV, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1702-2012 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Levetiracetam recalls

See all
Class I · High risk

Levetiracetam 0.75% in Sodium Chloride Injection 1

LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.

Ongoing Labeling / mix-up Dr. Reddy's Laboratories, Inc. NDC 43598-636-52 D-0365-2025
Class III · Low risk

Levetiracetam Tablets USP

Labeling; Wrong Barcode; error in the machine-readable barcode which could result in some units being read as Naproxen Tablets 500 mg. Product is labeled correctly as Levetiracetam

Terminated Labeling / mix-up McKesson Corporation dba McKesson Drug Company NDC 63739-795-10 D-0630-2021
Class II · Moderate risk

Levetiracetam Oral Solution

Defective container: Customer complaints for oral solution leaking from bottles.

Terminated Packaging defect Akorn, Inc. NDC 50383-241-16 D-0221-2021
Class II · Moderate risk

Levetiracetam Tablets

Presence of foreign tablet/capsule: A 1000 mg Levetiracetam Tablet was found in 500 gram bottle of Levetiracetam Tablets.

Terminated Particulate / foreign matter Eywa Pharma INC NDC 71930-063-52 D-0109-2021

Other recalls by Mylan Pharmaceuticals Inc.

All 2012 recalls
Class II · Moderate risk

Prasugrel Tablets

Failed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteria

Ongoing Dissolution failure Mylan Pharmaceuticals Inc NDC 0378-5186-93 D-0839-2026